Sexual intimacy after breast cancer: A systematic review of qualitative studies on women's and partners' experiences in dating and romantic relationships.

Body ImageAug 15, 2026 (epub)
Clinical ResearchOncology (Medical)Psychiatry

Holly Rea, Jane Meyrick, Helena Lewis-Smith

✦ AI-curated · Sources linked

In 30 seconds

This systematic review synthesizes qualitative studies on the impact of breast cancer on sexual intimacy and romantic relationships, including partners' perspectives. It identifies physical and psychological barriers to intimacy for women and their partners, emphasizing the role of body image. The review includes 24 studies with moderate to high methodological quality.

Key findings

  • Physical and psychological factors inhibit intimacy for women recovering from breast cancer and their partners.
  • Disclosure is crucial for intimacy progression in new post-diagnosis relationships.
  • Men in dating relationships often exhibit supportive and responsive behaviors.
  • Long-term relationships face challenges related to gender stereotypes and intimacy renegotiation.

Why it matters

Understanding the sexual and relational challenges faced by women with breast cancer and their partners is essential for healthcare professionals. Addressing these issues can improve quality of life and inform the development of targeted interventions.

Source

PubMed · PMID 42603448

Published in Body Image. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.